Studies on the mechanism of tolerance or graft-versus-host disease in allogeneic bone marrow recipients at the level of cytotoxic T-cell precursor frequencies.

Previous studies demonstrated that the frequency of donor-versus-host-reactive cytotoxic T-cell precursors (CTL-p) before allogeneic bone marrow transplantation (BMT) from matched unrelated donors correlates with the incidence of graft-versus-host disease (GvH-D). We investigated whether clinical manifestations of GvH-D after HLA-identical sibling BMT are accompanied by an increased frequency of minor histocompatibility antigen (HA)-specific CTL-p. We further asked whether changes of third-party-reactive CTL-p as a measure of overall immunocompetence are related to infectious complications frequently seen immediately after BMT. Eighteen patients (16 with an HLA-identical bone marrow graft, two with either one HLA-A or one HLA-DR mismatch) were studied. Limiting dilution analysis (LDA) was used to assess donor CTL-p frequencies against recipient pre-BMT, donor, and third-party targets in a follow-up study. Eight cases receiving HLA-identical marrow grafts never developed signs of GvH-D. Undetectable or very low frequencies (1/131,458) of minor HA-specific CTL-p were demonstrated pre-BMT. Two recipients, one of an HLA-A- and one of an HLA-DR-mismatched graft, exhibited low frequencies of recipient-specific CTL-p (1/66,920 and 1/85,577, respectively) before transplantation, which further decreased despite mild GvH-D grade I, or decreased within 3 months after grafting in the other case. Eight patients receiving HLA-identical grafts developed GvH-D. Recipient-specific CTL-p were less than 1/300,000 in five patients during limited GvH-D (four with grade I and one with grade II disease of the skin), but were detectable in three patients presenting with extensive GvH-D grades II to III and ranged from 1/7,993 to 1/210,108. The differences in post-BMT recipient-specific CTL-p frequencies between patients with GvH-D grades 0 to I (median, less than 1/300,000) and those with GvH-D grades II to III (median, 1/111,970) were statistically significant (P less than .05). Posttransplant lymphocytes from all 18 patients contained less than 1/300,000 CTL-p with specificity for donor targets. Comparison of third-party-reactive CTL-p frequencies between donor and post-BMT recipient lymphocytes showed a severe and long-lasting depletion subsequent to BMT, which was not related to infectious complications. Again, these differences reached the level of statistical significance (median CTL-p before BMT, 1/4,417; after BMT, 1/14,289; P less than .005).(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  H. Valdimarsson Cyclosporin A: the mechanism of action , 1994 .

[2]  A. Deisseroth,et al.  Bone marrow transplantation for leukemia. , 1993, The Journal of pediatrics.

[3]  A. Zwinderman,et al.  EFFECTOR MECHANISMS IN GRAFT‐VERSUS-HOST DISEASE IN RESPONSE TO MINOR HISTOCOMPATIBILITY ANTIGENS: I. ABSENCE OF CORRELATION WITH CYTOTOXIC EFFECTOR CELLS , 1990, Transplantation.

[4]  A. Zwinderman,et al.  EFFECTOR MECHANISMS IN GRAFT‐VERSUS-HOST DISEASE IN RESPONSE TO MINOR HISTOCOMPATIBILITY ANTIGENS: II. EVIDENCE OF A POSSIBLE INVOLVEMENT OF PROLIFERATIVE T CELLS , 1990, Transplantation.

[5]  B. Dupont,et al.  Both ongoing suppression and clonal elimination contribute to graft-host tolerance after transplantation of HLA mismatched T cell-depleted marrow for severe combined immunodeficiency. , 1990, Journal of immunology.

[6]  C. Huber,et al.  Studies of the mechanism of tolerance induced by short-term immunosuppression with cyclosporine in high-risk corneal allograft recipients. I. Analysis of CTL precursor frequencies. , 1989, Transplantation.

[7]  S. Mackinnon,et al.  Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. , 1989, Transplantation.

[8]  H. Sollinger,et al.  Enhancement of thyroid allograft survival following organ culture. Alteration of tissue immunogenicity. , 1989, Transplantation.

[9]  E. Holler,et al.  Improved survival following HLA-incompatible bone marrow transplantation. Munich Cooperative Group of Bone Marrow Transplantation. , 1989, Folia haematologica.

[10]  D. Sachs,et al.  MECHANISMS OF SUPPRESSION IN MIXED ALLOGENEIC CHIMERAS , 1988, Transplantation.

[11]  D. Niederwieser,et al.  IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. , 1988, Journal of immunology.

[12]  M. Ritter,et al.  Frequency analysis of cytotoxic T lymphocyte precursors--possible relevance to HLA-matched unrelated donor bone marrow transplantation. , 1988, Bone marrow transplantation.

[13]  C. Schmidt,et al.  Treatment of acute graft-versus-host disease after HLA-partially matched marrow transplantation with a monoclonal antibody (BMA031) against the T cell receptor. First results of a phase-I/II trial. , 1988, Onkologie.

[14]  J. Pepper,et al.  Rat heterotopic heart transplantation: quantification and analysis of cell mediated cytotoxicity. , 1988, Clinical and experimental immunology.

[15]  H. Deeg,et al.  Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Thomas,et al.  Marrow transplantation for malignant disease. , 1987, The American journal of the medical sciences.

[17]  W. Herzog,et al.  SELECTIVE REDUCTION OF DONOR‐SPECIFIC CYTOTOXIC T LYMPHOCYTE PRECURSORS IN PATIENTS WITH A WELL‐FUNCTIONING KIDNEY ALLOGRAFT , 1987, Transplantation.

[18]  A. Landay,et al.  CHARACTERIZATION OF CIRCULATING SUPPRESSOR T LYMPHOCYTES IN BONE MARROW TRANSPLANT RECIPIENTS , 1987, Transplantation.

[19]  B. Chapuis,et al.  Detection of anti-non-MHC-directed T cell reactivity following in vivo priming after HLA-identical marrow transplantation and following in vitro priming in limiting dilution cultures. , 1987, Transplantation proceedings.

[20]  M. López-Botet,et al.  Defective interleukin 2 receptor expression is associated with the T cell disfunction subsequent to bone marrow transplantation , 1987, European journal of immunology.

[21]  J. Meyers Infection in bone marrow transplant recipients. , 1986, The American journal of medicine.

[22]  H. Gerhartz,et al.  In vivo differentiation of leukaemic blasts and effect of low dose Ara‐C in a marrow grafted patient with leukaemic relapse , 1986, British journal of haematology.

[23]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[24]  L. Strijbosch,et al.  Analysis of cytotoxic T lymphocyte response in rejecting allografted canine kidneys. , 1986, Transplantation.

[25]  Jaap M Middeldorp,et al.  Cytomegalovirus immunity in allogeneic marrow grafting. , 1985, Transplantation.

[26]  R. Storb,et al.  Marrow transplantation from related donors other than HLA-identical siblings. , 1985, The New England journal of medicine.

[27]  G Opelz,et al.  CORRELATION OF HLA MATCHING WITH KIDNEY GRAFT SURVIVAL IN PATIENTS WITH OR WITHOUT CYCLOSPORINE TREATMENT: FOR THE COLLABORATIVE TRANSPLANT STUDY , 1985, Transplantation.

[28]  C. Orosz,et al.  ASSESSMENT OF IMMUNOCOMPETENCE BY LIMITING DILUTION ANALYSIS IN LONG‐TERM T CELL DEPLETION CHIMERAS TRANSPLANTED ACROSS THE MHC BARRIER , 1985, Transplantation.

[29]  S. Slavin,et al.  Functional clonal deletion versus active suppression in transplantation tolerance induced by total-lymphoid irradiation. , 1985, Transplantation.

[30]  R. Storb,et al.  Cellular interactions in marrow-grafted patients. III. Normal interleukin 1 and defective interleukin 2 production in short-term patients and in those with chronic graft-versus-host disease. , 1985, Transplantation.

[31]  G. Santos Bone marrow transplantation in leukemia: Current status , 1984, Cancer.

[32]  R. Mertelsmann,et al.  Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2. , 1984, Blood.

[33]  W. Friedrich,et al.  IMMUNORECONSTITUTION IN SEVERE COMBINED IMMUNODEFICIENCY AFTER TRANSPLANTATION OF HLA-HAPLOIDENTICAL, T-CELL-DEPLETED BONE MARROW , 1984, The Lancet.

[34]  D. Fradelizi,et al.  Inhibiton of IL 2 production after human allogeneic bone marrow transplantation. , 1983, Journal of immunology.

[35]  J. Vilček,et al.  Gamma interferon synthesis by human thymocytes and T lymphocytes inhibited by cyclosporin A. , 1983, Science.

[36]  J. Sprent,et al.  Lethal GVHD Across Minor Histocompatibility Barriers: Nature of the Effector Cells and Role of the H‐2 Complex , 1983, Immunological reviews.

[37]  J. Gratama,et al.  A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease , 1983, Nature.

[38]  K. Sullivan,et al.  Analysis of late infections after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. , 1982, Blood.

[39]  K. Lafferty,et al.  Inhibition of T‐Cell Activity by Cyclosporin A , 1982, Scandinavian journal of immunology.

[40]  R. Storb,et al.  Specific suppressor cells in graft–host tolerance of HLA-identical marrow transplantation , 1981, Nature.

[41]  C. Taswell,et al.  Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. , 1981, Journal of immunology.

[42]  M. Bevan,et al.  Anti-recipient cytotoxic T lymphocyte precursors are present in the spleens of mice with acute graft versus host disease due to minor histocompatibility antigens. , 1981, Journal of immunology.

[43]  Gale Rp Bone marrow transplantation in leukemia. , 1981 .

[44]  M. Röllinghoff,et al.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2 , 1981, European journal of immunology.

[45]  B. Speck Bone marrow transplantation in leukaemia (review). , 1981, Anticancer research.

[46]  C. Huber,et al.  Surface properties and in vitro functional capacities of human T lymphocyte subsets separated by linear density gradients. , 1979, Journal of immunology.

[47]  H. Flad,et al.  Expression and specificity of FcIgG receptor sites on neoplastic lymphocytes , 1978 .

[48]  R. Storb,et al.  Treatment of aplastic anemia by marrow transplantation from HLA identical siblings. Prognostic factors associated with graft versus host disease and survival. , 1977, The Journal of clinical investigation.

[49]  David Gottlieb,et al.  Mechanism of Action , 2012, Antibiotics.